ArticleDiabetes, obesity & metabolism2026
Association of GLP-1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimsTo evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes. MATERIALS AND
methodsThis retrospective active-comparator new-user cohort study utilised data from the National Institutes of Health's All of Us Research Program. Adult participants with Type 2 diabetes initiating GLP-1RAs or DPP4is without prior hepatic decompensation or competing causes of chronic liver disease were identified. Stratified propensity score matching (1:1) was employed to balance baseline covariates. The primary outcome was a composite of hepatic decompensation events (oesophageal varices with bleeding, ascites, hepatic encephalopathy, hepatic failure, or liver transplantation). Hazard ratios (HRs) were estimated using Cox proportional hazards regression.
resultsThe matched cohort included 7854 participants (mean age 57.3 years; 58.8% female; 24.8% Black or African American). GLP-1RA use was associated with a significantly reduced risk of hepatic decompensation compared with DPP4i use (HR 0.67; 95% CI 0.47-0.95; p = 0.026), corresponding to an absolute rate difference of -1.66 events per 1000 person-years. Estimates were directionally similar in prespecified sensitivity analyses.
conclusionsIn this diverse nationwide cohort, initiation of GLP-1RAs was associated with a significantly reduced risk of hepatic decompensation compared with DPP4is. These findings extend prior evidence by demonstrating this association in a cohort enriched for populations historically underrepresented in biomedical research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.